Page last updated: 2024-08-21

pyrazines and melphalan

pyrazines has been researched along with melphalan in 231 studies

Research

Studies (231)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's76 (32.90)29.6817
2010's155 (67.10)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Schlossman, R; Tai, YT1
Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M1
Adams, J; Altamirano, C; Berenson, JR; Borad, MJ; Frantzen, M; Friedman, JM; Ma, MH; Manyak, S; Mikail, A; Neeser, J; Parker, K; Roussos, E; Sjak-Shie, N; Vescio, RA; Wu, ZQ; Yang, HH1
Alsina, M; Djulbegovic, B; Durie, BG; Kumar, A; Loughran, T1
Berenson, JR; Schenkein, D; Vescio, R; Yang, HH1
Jagannath, S1
Dimopoulos, MA; Rahemtulla, A; Terpos, E1
Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R1
Joshua, DE1
Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH1
De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R1
Coiteux, V; Facon, T; Leleu, X1
Kyle, RA; Vincent Rajkumar, S1
Atadja, P; Carvajal-Vergara, X; Gutiérrez, N; López-Pérez, R; Maiso, P; Mateo, G; Ocio, EM; Pandiella, A; San Miguel, JF1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR1
Okamoto, S1
McKenna, KE; Morris, TC; Ramadan, KM1
Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P1
Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P1
Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J1
Iida, S3
Strobeck, M1
Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M1
Abouladze, M; Baudard, M; Dreano, M; Goldschmidt, H; Hose, D; Jourdan, M; Klein, B; Mahtouk, K; Moreaux, J; Rème, T; Robert, N; Romanelli, A; Rossi, JF; Vos, JD1
Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M1
Hulin, C1
Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C1
Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M1
Amiot, M; Anderson, KC; Chauhan, D; Gouill, SL; Harousseau, JL; Hideshima, T; Opferman, JT; Podar, K; Tai, YT; Zhang, J; Zorn, E1
Fassas, AB; Tricot, G1
Ganser, A; Peest, D1
Björkstrand, B; Gahrton, G1
Faiman, B1
Ishida, T2
Gotoh, A; Ohyashiki, K1
Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R2
DiPersio, JF; Fisher, NM; Peles, S; Tomasson, MH; Trivedi, R; Uy, GL; Vij, R; Zhang, QJ1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
López-Pérez, R; Montero, JC; Pandiella, A; San Miguel, JF1
Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O1
Garderet, L; Gorin, NC; Isnard, F1
Belch, AR; Debes Marun, C; Kirshner, J; Martin, LD; Pilarski, LM; Reiman, T; Thulien, KJ1
Facon, T; Hulin, C; Moreau, P2
Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H1
Durie, BG1
Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K1
Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A1
Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S1
Bladé, J; Rosiñol, L1
Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N1
DiPersio, JF; Fisher, NM; Goyal, SD; Oza, AY; Stockerl-Goldstein, K; Tomasson, MH; Uy, GL; Vij, R1
Ambrus, JL; Islam, A1
Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C1
Kami, M; Komatsu, T; Tsubokura, M1
Avvisati, G1
García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M1
Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C1
Higa, GM; Saad, AA; Sharma, M1
Abaya, CD; Berenson, JR; Cartmell, A; Duvivier, H; Eades, B; Flam, MS; Hilger, J; Nassir, Y; Patel, R; Swift, RA; Woytowitz, D; Yellin, O1
Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A1
Geffray, L1
Berenson, JR1
Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG1
Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H1
Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM1
Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H1
Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM1
Attal, M; Bourin, P; Laroche, M; Lemaire, O1
Kanda, Y1
Ozaki, S1
Berenson, JR; Campbell, RA; Chen, H; Li, ZW; Sanchez, E; Shalitin, D; Steinberg, J1
Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P1
Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN1
Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C1
Cherem, L; Kahan, BD; Kaposztas, Z; Katz, SM; Van Buren, CT1
Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C1
Azaïs, I; Brault, R; Debiais, F1
Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F1
Arvanitis, A; Caulder, E; Combs, AP; Favata, M; Fridman, JS; Kelley, JA; Li, J; Newton, R; Rogers, JD; Scherle, PA; Solomon, KA; Sparks, RB; Thomas, B; Vaddi, K; Wen, X1
Bauer, F; Dasanu, CA; Reale, MA1
Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E1
Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H1
Alexanian, R; Delasalle, K; Giralt, S; Wang, M1
Lonial, S1
Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E1
Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H1
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M1
Abdul-Jaleel, M; Candelaria-Quintana, D; Libby, E; Moualla, H; Rabinowitz, I1
Burbury, K; Harrison, SJ; Joyce, T; Peinert, S; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB1
Rajkumar, SV2
Flowers, CR; Harvey, RD; Heffner, LT; Kaufman, J; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; McMillan, S; Nooka, A; Renfroe, H; Tighiouart, M; Torre, C; Waller, EK1
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D1
Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL1
Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D1
Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P1
Palumbo, A1
Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K1
Cornell, LD; Fidler, ME; Nasr, SH; Qian, Q; Sethi, S1
Mateos, MV; San-Miguel, J1
Schots, R1
Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H1
Anderson, K; Cakana, A; Deraedt, W; Dimopoulos, M; Esseltine, DL; Hou, J; Khuageva, N; Kropff, M; Liu, K; Mateos, MV; Petrucci, MT; Richardson, P; Robak, T; Rossiev, V; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H; Vekemans, MC1
Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y1
Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR1
Alvarez Fernández, GM; de Alarcón Jiménez, RM; García Hernández, MA; Jimeno Griñó, C; Molina Núñez, M; Navarro Parreño, MJ; Roca Meroño, S; Zarco Pedrinaci, E1
Azab, AK; Bahlis, NJ; Boise, LH; Brentnall, M; Duggan, P; Ghobrial, IM; Gratton, K; Klimowicz, AC; Lin, C; Mansoor, A; Neri, P; Ren, L; Stewart, DA; Tassone, P1
Abraham, J; Bridoux, F; Delbès, S; Desport, E; Fermand, JP; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G1
Kyle, RA; Steensma, DP1
Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M1
Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G1
Brugnatelli, S; Foli, A; Invernizzi, R; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Russo, P1
Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W1
Henderson, RA; McGhee, CN; Patel, D; Pradhan, MA; Vincent, AL1
Burns, CJ; Khong, T; Monaghan, KA; Spencer, A1
Bello, C; Comenzo, RL; Hassoun, H; Hoover, E; Landau, H; Nimer, SD; Riedel, ER1
Andrea, NT; Quillen, K; Sanchorawala, V; Seldin, DC; Sloan, JM1
Falk, RH1
Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M1
Bousquet, A; Join-Lambert, O; Malfuson, JV; Martinaud, C; Soler, C1
Kuwabara, S1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O1
Bryant, J; Clegg, AJ; Cooper, K; Picot, J1
Bridoux, F; Delbes, S; Desport, E; Fermand, JP; Jaccard, A; Pourreau, F; Puyade, M; Sirac, C; Touchard, G1
Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M1
Pan, XJ; Xiao, W; Yang, ZH; Zheng, CY; Zhou, SY; Zhu, MX1
Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S1
Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A1
Knop, S1
Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN1
Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H1
Domján, G; Gadó, K1
Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF1
Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D1
Chigira, N; Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Shirane, S; Sugimoto, K; Wakabayashi, M1
Charliński, G; Jedrzejczak, WW; Wiater, E1
Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M1
Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Gul, Z; Lum, L; Mellon-Reppen, S; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E1
Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T; Yamakawa, M1
Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M1
Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L1
Suzuki, K2
Harousseau, JL1
Bello, C; Comenzo, RL; Flombaum, C; Giralt, S; Hassoun, H; Hoover, E; Landau, H; Liu, J; Maurer, M; Riedel, E; Rosenzweig, MA1
Synhaeve, NE; Tijssen, CC; van der Heul, C1
Cavenagh, J; Joel, S; Maharaj, L; Oakervee, H; Popat, R1
Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A1
Giralt, S; Landau, H; Rosenzweig, M1
Burbury, K; Doo, NW; Harrison, SJ; Joyce, T; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M1
Miwa, A1
Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C1
Gertz, MA; Hayman, SR; Sher, T1
Hildebrandt, GC; Panu, LD; Shahan, JL1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H1
Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST1
Lonial, S; Miguel, JF1
Mina, R; Palumbo, A1
Collet, P; Marotte, H; Nizeica, V1
Li, J; Zhou, DB1
Davies, FE; Fryer, RA; Graham, TJ; Morgan, GJ; Robinson, SP; Smith, EM; Walker-Samuel, S1
Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D1
Ando, K; Hotta, T; Iida, S; Ishii, M; Matsue, K; Matsumoto, M; Mukai, HY; Ogawa, Y; Ogura, M; Ohashi, K; Sakai, A; Suzuki, K; Terui, Y; Tobinai, K1
Kim, JA; Kwak, JY; Lee, BH; Min, CK; Shin, SH; Yhim, HY1
Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A1
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G1
Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M1
Akashi, K; Choi, I; Ito, Y; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shiratsuchi, M; Takamatsu, Y; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G1
El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW1
Bakhous, A; Waheed, S; Zhu, H1
Morgan, GJ1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K1
Drach, J; Drach-Schauer, B; Eder, S; Lamm, W1
Bačovský, J; Látalová, P; Lochman, P; Metelka, R; Minařík, J; Pika, T; Ščudla, V; Vymětal, J; Zapletalová, J1
Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S1
Hahn, T; McCarthy, PL1
Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y1
Furukawa, Y; Hatano, K; Kikuchi, J; Nagai, T; Ozawa, K; Sripayap, P1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM1
Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R1
Bryant, J; Clegg, A; Cooper, K; Picot, J1
Demirayak, Ş; Yurttaş, L1
Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z1
Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N1
Abar, F; Dibb, J; Dibb, W; Frires, R; Heitner, SB; Kovacsovics, T; Maziarz, RT; Meyers, G; Perez-Avraham, G; Scott, EC; Smith, SD; Stentz, A1
Corchete, LA; Garayoa, M; García-Sanz, R; Gutiérrez, NC; Krzeminski, P; Ocio, EM; Paíno, T; Paiva, B; Redondo, A; San-Miguel, JF; San-Segundo, L; Sarasquete, ME1
Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M1
Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K1
Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H1
Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT1
Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H1
Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N1
Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K1
Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G1
Basset, M; Foli, A; Lavatelli, F; Merlini, G; Milani, P; Nuvolone, M; Obici, L; Palladini, G; Perlini, S; Vidus Rosin, M1
Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI1
Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J1
Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK1
Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M1
Choi, JO; Jeon, ES; Kim, HJ; Kim, JS; Kim, K; Kim, SJ; Lee, GY; Lee, JE; Lee, JY; Lee, SY; Lim, SH; Min, JH1
Nakaseko, C1
Tsurumi, H1
Bartlett, DL; Kim, SY; Kwon, YT; Lee, YJ; Song, X; Tang, D; Zhang, L1
Gertz, MA1
Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A1
Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H1
Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK1
Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W1
Houghton, PJ; Kang, M; Kurmashev, D; Kurmasheva, RT; Reynolds, CP; Smith, MA; Wu, J1

Reviews

52 review(s) available for pyrazines and melphalan

ArticleYear
High-dose therapy and immunomodulatory drugs in multiple myeloma.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide

2002
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
    The Lancet. Oncology, 2003, Volume: 4, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2003
Treatment of myeloma in patients not eligible for transplantation.
    Current treatment options in oncology, 2005, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide

2005
Current treatment options for myeloma.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine

2005
New treatments for multiple myeloma.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2005
[Prognostic factors and new treatments of multiple myeloma].
    La Revue du praticien, 2006, Jan-15, Volume: 56, Issue:1

    Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2006
Treatment of multiple myeloma: an emphasis on new developments.
    Annals of medicine, 2006, Volume: 38, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2006
[Recent progress in diagnosis of and therapy for multiple myeloma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2006, Sep-10, Volume: 95, Issue:9

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide

2006
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Oncology, 2006, Volume: 70, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide

2006
[Recent progress in the treatment of multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:2

    Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide

2007
[New treatment of multiple myeloma].
    La Revue de medecine interne, 2007, Volume: 28, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide

2007
Tandem transplants in the treatment of multiple myeloma. Pro.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2004
[Therapy of multiple myeloma: indications and options].
    Der Internist, 2007, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden

2007
High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Seminars in hematology, 2007, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Registries; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2007
Clinical updates and nursing considerations for patients with multiple myeloma.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome

2007
[Chemotherapy for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine

2007
[Role of bortezomib in the treatment of multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide

2007
Frontline treatment of multiple myeloma in elderly patients.
    Blood reviews, 2008, Volume: 22, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide

2008
[Treatment for multiple myeloma: current status and future strategy in Japan].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous

2008
Advances in therapy of multiple myeloma.
    Current opinion in oncology, 2008, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome

2008
Treatment of multiple myeloma in the targeted therapy era.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning

2009
Multiple myeloma.
    Lancet (London, England), 2009, Jul-25, Volume: 374, Issue:9686

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome

2009
[Hematopoietic stem cell transplantation for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine

2009
[New treatment strategies for multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine

2009
New treatments for myeloma.
    Joint bone spine, 2010, Volume: 77, Issue:1

    Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide

2010
New developments in the treatment of patients with multiple myeloma.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide

2010
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-20, Volume: 28, Issue:33

    Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous

2010
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
    American journal of hematology, 2011, Volume: 86, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2011
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
    Current hematologic malignancy reports, 2011, Volume: 6, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2011
[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:2

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chronic Disease; Combined Modality Therapy; Dexamethasone; Down-Regulation; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin lambda-Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Remission Induction; Renal Dialysis; Transplantation, Autologous

2011
[Current treatment of AL amyloidosis].
    Nephrologie & therapeutique, 2011, Volume: 7, Issue:6

    Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development Conferences as Topic; Dexamethasone; Drug Therapy, Combination; Heart Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Transplantation; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Paraproteinemias; Paraproteins; Peptide Fragments; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide

2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2011
[New insights in the treatment of myeloma with renal failure].
    Nephrologie & therapeutique, 2011, Volume: 7, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide

2011
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Combined Modality Therapy; Demyelinating Diseases; Humans; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Pyrazines; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A

2010
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:41

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide

2011
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:3 Pt 1

    Topics: Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Heart Transplantation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Kidney Transplantation; Melphalan; Paraproteinemias; Plasma Exchange; Pyrazines

2012
[Multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid

2012
[AL amyloidosis].
    Orvosi hetilap, 2012, Apr-15, Volume: 153, Issue:15

    Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Heart Failure; Humans; Lenalidomide; Melphalan; Myocardium; Palliative Care; Patient Selection; Prognosis; Pyrazines; Quality of Life; Risk Assessment; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2012
Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:11

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Boronic Acids; Bortezomib; Fatal Outcome; Humans; Leukemia, Plasma Cell; Male; Melphalan; Pleural Effusion, Malignant; Prednisone; Pyrazines; Treatment Failure

2012
Fifty years of melphalan use in hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous

2013
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
    Clinical and experimental nephrology, 2012, Volume: 16, Issue:5

    Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide

2012
Light-chain amyloidosis: SCT, novel agents and beyond.
    Bone marrow transplantation, 2013, Volume: 48, Issue:8

    Topics: Amyloidosis; Animals; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Melphalan; Pyrazines; Survival Analysis; Thalidomide

2013
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome

2012
Current therapeutic strategy for multiple myeloma.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid

2013
Induction therapy for newly diagnosed multiple myeloma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2013
Part II: role of maintenance therapy in transplant-ineligible patients.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine

2013
New advances in the diagnosis and treatment of POEMS syndrome.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A

2013
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
    Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013

    Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning

2013
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
    Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2014
[Treatment of transplant-eligible symptomatic multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning

2014
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide

2014
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    American journal of hematology, 2014, Volume: 89, Issue:12

    Topics: Age Factors; Amyloidosis; Antineoplastic Agents; Biomarkers; Bone Marrow; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Pyrazines; Stem Cell Transplantation; Subcutaneous Fat; Survival Analysis; Troponin T

2014

Trials

58 trial(s) available for pyrazines and melphalan

ArticleYear
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
    Clinical lymphoma, 2003, Volume: 4, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Safety; Treatment Outcome

2003
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-20, Volume: 24, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome

2006
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
    Blood, 2006, Oct-01, Volume: 108, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines

2006
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Clinical lymphoma & myeloma, 2006, Volume: 6, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide

2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
    Blood, 2007, Apr-01, Volume: 109, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide

2007
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
    Haematologica, 2007, Volume: 92, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine

2007
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome

2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2007
Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:9

    Topics: Adult; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Multiple Myeloma; Osteoclasts; Patient Selection; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous

2007
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Haematologica, 2008, Volume: 93, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis

2008
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Annals of hematology, 2008, Volume: 87, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia

2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome

2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Leukemia, 2008, Volume: 22, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide

2008
Update on recent developments for patients with newly diagnosed multiple myeloma.
    Annals of the New York Academy of Sciences, 2008, Volume: 1138

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2008
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
    Bone marrow transplantation, 2009, Volume: 43, Issue:10

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Lymphocyte Subsets; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Autologous; Treatment Outcome; Virus Activation

2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    British journal of haematology, 2009, Volume: 144, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia

2009
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
    European journal of haematology, 2009, Volume: 82, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome

2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome

2010
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome

2009
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Blood, 2010, Jan-07, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2010
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
    Annals of hematology, 2010, Volume: 89, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome

2010
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome

2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States

2010
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
    Leukemia research, 2010, Volume: 34, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome

2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Blood, 2010, Nov-11, Volume: 116, Issue:19

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome

2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome

2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation Conditioning

2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
    Blood, 2010, Dec-02, Volume: 116, Issue:23

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome

2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
    European journal of haematology, 2011, Volume: 86, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors

2011
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States

2012
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome

2010
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
    European journal of haematology, 2011, Volume: 86, Issue:5

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant

2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
    British journal of haematology, 2011, Volume: 153, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Erythrocyte Transfusion; Female; Hematinics; Humans; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Survival Rate; Thromboembolism

2011
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous

2011
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
    Haematologica, 2011, Volume: 96, Issue:12

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
    Cancer, 2012, May-01, Volume: 118, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning

2012
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Blood, 2011, Nov-24, Volume: 118, Issue:22

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2011
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
    European journal of haematology, 2012, Volume: 88, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide

2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
    European journal of haematology, 2012, Volume: 89, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome

2012
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
    Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Female; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous

2012
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.
    Leukemia, 2013, Volume: 27, Issue:4

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Melphalan; Middle Aged; Pyrazines; Stem Cell Transplantation

2013
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
    Cancer, 2013, Mar-01, Volume: 119, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence

2013
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-01, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome

2013
Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Treatment Outcome

2013
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    International journal of hematology, 2013, Volume: 98, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning; Transplantation, Autologous

2013
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous

2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome

2014
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    European journal of haematology, 2014, Volume: 93, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome

2014
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    Blood, 2014, Jun-26, Volume: 123, Issue:26

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate

2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous

2014
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning

2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
    Blood, 2014, Sep-18, Volume: 124, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2014
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
    American journal of hematology, 2015, Volume: 90, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis

2015

Other Studies

121 other study(ies) available for pyrazines and melphalan

ArticleYear
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
    Blood, 2003, Mar-15, Volume: 101, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Recurrence; Tumor Cells, Cultured

2003
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:3

    Topics: Active Transport, Cell Nucleus; Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Nucleus; Cell Survival; Cysteine Endopeptidases; Cytosol; Dose-Response Relationship, Drug; Genes, Dominant; Humans; I-kappa B Proteins; Melphalan; Microscopy, Fluorescence; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured; Ubiquitin

2003
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin

2005
Multiple myeloma: the present and the future.
    The Medical journal of Australia, 2005, Oct-03, Volume: 183, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2005
Bortezomib-induced Sweet's syndrome.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases

2005
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Cancer research, 2006, Jun-01, Volume: 66, Issue:11

    Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Melphalan; Multiple Myeloma; Panobinostat; Pyrazines

2006
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    The Lancet. Oncology, 2006, Volume: 7, Issue:11

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid

2006
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
    Cancer research, 2007, Feb-15, Volume: 67, Issue:4

    Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation

2007
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous

2007
Multiple myeloma therapies.
    Nature reviews. Drug discovery, 2007, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide

2007
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; I-kappa B Kinase; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Pyrimidines

2007
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
    British journal of haematology, 2007, Volume: 138, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays

2007
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Oncogene, 2008, Jan-31, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Up-Regulation

2008
Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
    Leukemia research, 2008, Volume: 32, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines

2008
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
    Haematologica, 2008, Volume: 93, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Protein Isoforms; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2008
[Treatment of myeloma in the elderly].
    Bulletin du cancer, 2008, May-28, Volume: 95 FMC Onco

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide

2008
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
    Blood, 2008, Oct-01, Volume: 112, Issue:7

    Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Aberrations; Clone Cells; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Melphalan; Models, Biological; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Rats; Stromal Cells; Tumor Cells, Cultured

2008
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
    International journal of hematology, 2008, Volume: 88, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous

2008
Treatment of myeloma--are we making progress?
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines

2008
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation

2009
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    International journal of oncology, 2008, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine

2008
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Experimental cell research, 2009, Feb-01, Volume: 315, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; G1 Phase; Humans; Imidazoles; Melphalan; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Recombinant Proteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases

2009
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2008
New evidence in oncologic and cardiocirculatory medicine.
    Internal and emergency medicine, 2009, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines

2009
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate

2008
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide

2008
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Dermatology online journal, 2008, Nov-15, Volume: 14, Issue:11

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine

2008
Cutaneous involvement in multiple myeloma and bortezomib.
    Annals of hematology, 2009, Volume: 88, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia

2009
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide

2009
Hematology: Bortezomib in newly diagnosed multiple myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome

2009
Successful bortezomib-based treatment in POEMS syndrome.
    European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine

2009
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine

2010
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays

2010
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide

2010
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Cancer research, 2009, Dec-15, Volume: 69, Issue:24

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB

2009
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
    British journal of haematology, 2010, Volume: 148, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2010
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Transplantation proceedings, 2009, Volume: 41, Issue:10

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Pyrazines; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2009
Treatment of multiple myeloma: 2009 update.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2009
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Melphalan; Mice; Mice, SCID; Molecular Structure; Multiple Myeloma; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyridines; STAT3 Transcription Factor; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays

2010
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous

2010
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous

2010
Frontline regimens for multiple myeloma patients.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2010
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine

2010
Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Leukemia, Plasma Cell; Melphalan; Prednisolone; Pyrazines; Remission Induction

2010
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous

2011
Optimising bortezomib in newly diagnosed multiple myeloma.
    The Lancet. Oncology, 2010, Volume: 11, Issue:10

    Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome

2010
First-line treatment of elderly multiple myeloma patients.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide

2010
De novo AL amyloidosis in the kidney allograft.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:3

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Transplantation; Male; Melphalan; Middle Aged; Prednisone; Proteinuria; Pyrazines; Remission Induction; Treatment Outcome

2011
Recent advances in myeloma treatment.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide

2011
[A case of aggressive multiple myeloma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines

2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous

2011
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Blood, 2011, Jun-09, Volume: 117, Issue:23

    Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Boronic Acids; Bortezomib; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Fibronectins; Focal Adhesion Kinase 1; Gene Knockdown Techniques; Gene Silencing; Humans; Integrin beta Chains; Melphalan; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-maf; Pyrazines; rac1 GTP-Binding Protein; src-Family Kinases; Stem Cell Transplantation; Sumoylation; Transcription Factor RelA; Transplantation, Autologous; Transplantation, Heterologous; Vascular Endothelial Growth Factor A

2011
History of multiple myeloma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane

2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Annals of hematology, 2012, Volume: 91, Issue:1

    Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Lenalidomide; Male; Melphalan; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome

2012
Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy.
    Cornea, 2011, Volume: 30, Issue:10

    Topics: Amyloid; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Corneal Dystrophies, Hereditary; Dexamethasone; DNA Mutational Analysis; Extracellular Matrix Proteins; Gelsolin; Glucocorticoids; Humans; Immunoglobulin Heavy Chains; Male; Mass Spectrometry; Melphalan; Microscopy, Confocal; Middle Aged; Mutation; Nephrotic Syndrome; Paraproteinemias; Pyrazines; Sequence Analysis, Protein; Transforming Growth Factor beta

2011
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Leukemia, 2011, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Janus Kinase 1; Melphalan; Multiple Myeloma; Phosphorylation; Pyrazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Stromal Cells

2011
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2011, Volume: 18 Suppl 1

    Topics: Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Melphalan; Pyrazines; Stem Cell Transplantation

2011
Cardiac amyloidosis: a treatable disease, often overlooked.
    Circulation, 2011, Aug-30, Volume: 124, Issue:9

    Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Boronic Acids; Bortezomib; Calcium Channel Blockers; Dexamethasone; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Lenalidomide; Melphalan; Middle Aged; Myocardium; Prealbumin; Pyrazines; Severity of Illness Index; Stem Cell Transplantation; Thalidomide; Treatment Outcome

2011
[Pneumonia and Rothia dentocariosa].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:11

    Topics: Actinomycetales Infections; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunocompromised Host; Melphalan; Micrococcaceae; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Pyrazines

2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2012
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
    Cancer research, 2012, Mar-15, Volume: 72, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide

2012
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
    International journal of oncology, 2012, Volume: 40, Issue:6

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunoglobulin G; Lung Neoplasms; Matrix Metalloproteinase 2; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrazines; Xenograft Model Antitumor Assays

2012
Timing of the high-dose therapy in the area of new drugs.
    Srpski arhiv za celokupno lekarstvo, 2011, Volume: 139 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous

2011
[Current perspectives in the treatment of multiple myeloma - news and views].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:13

    Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous

2012
Multiple myeloma: treatment evolution.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult

2012
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190

    Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide

2012
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11

    Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation

2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine

2013
[A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Doxorubicin; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melphalan; Middle Aged; Mitolactol; Mitomycins; Neuroectodermal Tumors, Primitive; Pyrazines; Salvage Therapy; Suicide; Tomography, X-Ray Computed

2012
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis.
    Acta dermato-venereologica, 2013, Mar-27, Volume: 93, Issue:2

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome

2013
How to select among available options for the treatment of multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
Intracranial mass of multiple myeloma with good response to chemotherapy.
    BMJ case reports, 2012, Sep-30, Volume: 2012

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome

2012
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
    British journal of haematology, 2013, Volume: 160, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Pyrazines

2013
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Transplantation Conditioning; Treatment Outcome

2013
[Diagnosis and treatment for plasma cell leukemia].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Plasma Cell; Melphalan; Pyrazines; Rituximab; Thalidomide

2012
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome

2013
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:10

    Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Melphalan; Myeloablative Agonists; Myocardium; Pyrazines; Steroids; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome

2012
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide

2012
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
    The oncologist, 2013, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States

2013
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid

2013
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genes, Reporter; Graft Survival; Humans; Injections; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Melphalan; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Paraproteins; Plasma Cells; Pyrazines; Syndecan-1; Tibia; Tumor Microenvironment

2013
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
    Bone marrow transplantation, 2013, Volume: 48, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    International journal of hematology, 2013, Volume: 97, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Risk Factors; Transplantation, Autologous; Treatment Outcome

2013
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine

2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine

2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy

2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult

2013
Multiple myeloma: a descriptive study of 217 Egyptian patients.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine

2014
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid

2013
Transplants for the elderly in myeloma.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide

2013
Myeloma presenting during pregnancy.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous

2014
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
    Oncology, 2013, Volume: 85, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2013
[Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:5

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Heart Neoplasms; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Melphalan; Middle Aged; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome

2013
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous

2014
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    American journal of hematology, 2014, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Anticancer research, 2013, Volume: 33, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning

2013
Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
    Acta haematologica, 2014, Volume: 132, Issue:1

    Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Line; Depsipeptides; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Integrin alpha4; Integrin beta1; Melphalan; Multiple Myeloma; Pyrazines; RNA, Messenger; RNA, Neoplasm; Syndecan-1

2014
Comparative cost-effectiveness models for the treatment of multiple myeloma.
    International journal of technology assessment in health care, 2014, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom

2014
Synthesis and anticancer activity of some 1,2,3-trisubstituted pyrazinobenzimidazole derivatives.
    Journal of enzyme inhibition and medicinal chemistry, 2014, Volume: 29, Issue:6

    Topics: Acetophenones; Antineoplastic Agents; Benzimidazoles; Benzylamines; Carbonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Design; Humans; Melphalan; Molecular Structure; Potassium; Pyrazines; Structure-Activity Relationship

2014
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
    Leukemia, 2014, Volume: 28, Issue:8

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9

2014
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
    International journal of hematology, 2014, Volume: 99, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome

2014
Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adult; Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiomyopathies; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Kidney Diseases; Lenalidomide; Male; Melphalan; Middle Aged; Myeloablative Agonists; Proteasome Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2014
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Copy Number Variations; Doxorubicin; Heterografts; Humans; Immunophenotyping; Melphalan; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Phenotype; Plasma Cells; Precursor Cells, B-Lymphoid; Pyrazines; Syndecan-1

2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases

2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    American journal of hematology, 2014, Volume: 89, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
    Haematologica, 2014, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome

2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors

2014
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide

2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine

2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide

2014
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
    Leukemia, 2014, Volume: 28, Issue:12

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Dexamethasone; Humans; Immunoglobulin Light Chains; Melphalan; Middle Aged; Pyrazines; Treatment Outcome

2014
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine

2014
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    Genes, chromosomes & cancer, 2015, Volume: 54, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines

2015
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Journal of medical case reports, 2014, Sep-08, Volume: 8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous

2014
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2014, Volume: 21, Issue:4

    Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Prednisolone; Pyrazines; Retrospective Studies

2014
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
    Cell death & disease, 2014, Oct-30, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Kinetics; Melphalan; Membrane Proteins; Mice; Mitochondria; Phosphorylation; Phosphoserine; Pyrazines; Sirolimus

2014
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
    Oncology research and treatment, 2014, Volume: 37, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries

2014
[Complications and managements in treatment of melphalan, prednisone and new agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide

2015
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
    Acta haematologica, 2015, Volume: 134, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide

2015
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
    American journal of hematology, 2015, Volume: 90, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis

2015
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cisplatin; Female; Humans; Isoxazoles; Melphalan; Mice; Mice, SCID; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2018